The FDA plans to introduce a faster approval process for custom gene-editing therapies, allowing combined trials for patients with related rare genetic disorders, Bloomberg’s Gerry Smith reports. This shift aims to accelerate one-time, potentially curative treatments for very small patient populations and encourage industry investment. The move reflects the agency’s effort to adapt regulation to rapid scientific advances like CRISPR. Publicly traded stocks in the sector include Crispr Therapeutics (CRSP) and Editas Medicine (EDIT).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Video: This stock is dragging down the in vivo gene editing therapy space
- Editas Medicine’s Long-Term Study on EDIT-301: A Potential Game-Changer for Hemoglobinopathies
- Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
- Intellia Therapeutics price target lowered to $30 from $36 at BofA
- Editas Medicine management to meet with Cantor